ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0138

Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0455

Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0392

Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0334

Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0250

Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0476

Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0204

Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0390

Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0009

Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 0366

Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0379

Physical Activity Is Associated with Physical and Global Function in Patients with Axial Spondyloarthritis, Independent of Disease Activity

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0056

Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic

Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

1:00PM-3:00PM: Abstract Number: 0040

Plasma Proteomic Signatures in Juvenile Dermatomyositis Highlight Novel Proteins and a Protein Module That Associate with Skin and Global Disease Activity

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: PP16

Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0132

Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].